Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Abbvie Inc chart...

About the Company

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.

CEO

Richard Gonzalez

Exchange

NEW YORK STOCK EXCHANGE INC.

Website

https://www.abbvie.com/

$54B

Total Revenue

50K

Employees

$317B

Market Capitalization

53.87

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ABBV News

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

6d ago, source: Zacks.com on MSN

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today

17h ago, source:

Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 10 years ago, it would be worth $347.98 today based on a price of $179.33 for ABBV at the time of writing.

AbbVie Stock: I Was So Wrong, But This Is Way Too Fast

9d ago, source:

AbbVie Inc.'s ability to overcome challenges, strong revenue growth, and reduced risks make investors optimistic. Click for ...

Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight

27d ago, source: Yahoo Finance

AbbVie Inc's robust immunology and oncology portfolio drives its competitive edge. Patent expirations and biosimilar competition present significant challenges. Continued investment in R&D and ...

Client Profile: AbbVie Inc

27d ago, source: OpenSecrets.org

AbbVie Inc $7,000,000 Dorcas Adekunle No Revolving Door Profiles Non Former Members of Congress AbbVie Inc $7,000,000 Daniel Bachner Revolving Door Profiles Non Former Members of Congress AbbVie Inc ...

AbbVie Loses Appeal to Keep Documents in AndroGel Suit Secret

7d ago, source:

AbbVie Inc.‘s assertion that documents, created during a patent dispute involving the low testosterone drug AndroGel 1% were protected by attorney-client privilege, was rejected by the Third Circuit ...

AbbVie's Allergan Aesthetics Gets FDA Nod For Juvederm Voluma XC For Temple Hollows

13d ago, source: Business Insider

(RTTNews) - Drug manufacturer AbbVie Inc. (ABBV), Tuesday announced that its subsidiary Allergan Aesthetics received approval from the U.S. Food and Drug Administration or FDA regarding Juvederm ...

AbbVie recognised among Best Large Workplaces in Ireland

3d ago, source: Western People

AbbVie, the global biopharmaceutical company, has been listed as one of the best places to work in Ireland at the 2024 Great ...

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

6d ago, source: Yahoo Finance

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...